Shah Capital Management has withdrawn a proxy campaign against the re-election of directors at vaccines firm Novavax in the wake of its $1.2 billion alliance with Sanofi.
AstraZeneca is backing up its considerable investment in antibody-drug conjugates (ADCs) for cancer with the construction of a $1.5 billion new facility in Singapore to ma
A report issued by the office of US Senator Bernie Sanders has claimed that the high prices being charged for new GLP-1 agonist-based obesity therapies like Novo Nordisk’s
Amgen has doubled its range of bispecific T-cell engager (BiTE) drugs with the FDA approval of tarlatamab for advanced small cell lung cancer (SCLC) after a priority revie
Bristol-Myers Squibb has chalked up another FDA approval for its CD19-directed CAR-T therapy Breyanzi, this time as a third-line or later therapy for follicular lymphoma (
Eisai and Biogen have filed a rolling biologics license application in the US for a subcutaneous formulation of Alzheimer’s disease therapy Leqembi that was delayed by the